much-quoted WHO’s estimate that 80%of people worldwide rely on traditionalmedicine <strong>for</strong> their primary healthcare.The majority of these people are indeveloping countries, where rapidpopulation growth is expected to increasepressures on medicinal plant resources.The greater part of traditional therapyinvolves the use of plants. With little orno access to modern pharmaceuticalsand a strong cultural preference <strong>for</strong>traditional medicine, medicinal plants arethere<strong>for</strong>e fundamental to the well-being ofbillions of people.Demand <strong>for</strong> traditional remedies is alsoincreasing in so-called developedcountries, alongside growingenvironmental awareness and a desire<strong>for</strong> natural healing through naturalproducts.‘Modern’ medicineOf course, allopathic or ‘modern’medicine also owes a great deal tomedicinal plants. Catharanthus roseus<strong>for</strong> example, treats leukaemia andHodgkin’s disease. Morphine andcodeine are produced from cultivatedopium poppy, Papaver somniferum.Aspirin was originally found in willow bark(Salix spp.). Quinine from the cinchonatree has been the primary treatment <strong>for</strong>malaria <strong>for</strong> centuries. Digitalin medicines,Digitalis spp.extracted from the leaves of the commonfoxglove (Digitalis spp.), are widely used<strong>for</strong> a variety of heart conditions. Topicalsteroids <strong>for</strong> eczema are produced fromthe yam (Dioscorea spp.) or from sisal(Agave spp.) and the alkaloidGalantamine, sourced from the bulbs ofsnowdrops (Galanthus spp.) is used totreat Alzheimer’s disease, slowing downthe progression of dementia.In many cases modern chemistry cannotoffer viable alternatives to activebotanical compounds. The compoundpaclitaxel (found in Taxus spp. and sourceof the anti-cancer drug, taxol) wasdescribed as the kind of molecule that nochemist would ever sit down and think ofmaking;“If contemporary chemistry is nowallowing us to merely copy suchmolecules, one can imagine the nearimpossibility of designing from scratch amolecule with a comparable combinationof <strong>for</strong>m and biological function”(Capson, 2004).Predictions that advances in chemicalsciences and synthetic materialdevelopment would lessen the need <strong>for</strong>natural materials have proved to bewrong, and modern medicine dependson the continuing availability ofbiological materials as anincomparable source of moleculardiversity.Taxus spp.In fact, as many as 50% of prescriptiondrugs are based on a molecule thatoccurs naturally in a plant, with some25% of prescription drugs derived directlyfrom flowering plants or modelled on plantmolecules (Foster and Johnson, 2006).<strong>Plants</strong> <strong>for</strong> <strong>life</strong>: Medicinal plant conservation and botanic gardens 7
4. Medicinal plants <strong>for</strong> livelihoodsMedicinal plants are clearly an importantglobal resource in terms of healthcare butthey are also an important economicresource, traded extensively on scalesranging from the local to the international.Internationally, the trade in medicinalplants is estimated to be worth $60 billionper year (World Bank, 2004) increasing ata rate of 7% a year (Koul and Wahab,2004).Very little of the raw material to supplythis demand is from cultivated sources.Of the 3000 or so species known to be ininternational trade (Schippmann et al,2006) there are approximately 900 <strong>for</strong>which commercial cultivation is underwayor in development (Mulliken and Inskipp,2006). Putting it another way, about 70-80% of the medicinal plants being tradedin the world’s most important rangecountries <strong>for</strong> medicinal plants originatefrom wild-collection (WWF/TRAFFICGermany, 2002). Many of these speciesare widespread and abundant but <strong>for</strong>naturally rare and heavily exploitedspecies wild collection can be a majorthreat with local extinction the outcome.It is the collection <strong>for</strong> commercial traderather than home-use that isoverwhelmingly the problem (Hamilton,2003).Though notoriously poorlydocumented, and though ourunderstanding of the biology, ecologyand status in the wild of mostmedicinal plants is very fragmented,this level of wild harvest is said to becurrently unsustainable.We know this because herb-gatherers arehaving to go farther and farther afield toharvest the plant they want; they’reexperiencing a drop in harvest levels.Some species just aren’t there anymore.Un<strong>for</strong>tunately, the motivation of shorttermprofit increase neglects allconsiderations of sustainability, butconservation intervention can occur atseveral points along the supply chain.The consequences of unsustainableharvest are far-reaching, and not simplyconfined to a loss of healthcare orbiodiversity. Many of the world’s poorestpeople rely on the collecting and sellingof wild medicinal plants <strong>for</strong> incomegeneration. Though prices paid togatherers tend to be very low medicinalplant collection provides a significantincome <strong>for</strong> the often marginal, rural poor(World Bank, 2004).Gentiana luteaGentiana lutea (Yellowgentian) is found in themountains of central andsouthern Europe. Gentianroot (which can be asthick as a person’s arm)has a long history of useas an herbal bitter in thetreatment of digestivedisorders. An Egyptianpapyrus from 1200 B.C.mentions gentian as aningredient in medicines(Foster and Johnson,2006).The root contains one ofthe bitterest substancesknown to science (thebitter taste can still be detected atdilutions of herb to water 1:20,000) andit stimulates the taste buds and brainreflexes to promote the secretion of salivaand gastric juices. As such it has beenused as an appetite stimulant in thetreatment of anorexia (Foster, 2006).It is said to be especially useful in statesof exhaustion from chronic disease andin cases of debility or weakness of thedigestive system; strengthening the humansystem by stimulating the liver, gall bladderand digestive system (<strong>Plants</strong> <strong>for</strong> a Future,2004).Most imports of G.lutea originate fromwild harvest and occasionally fromcultivation in south east Europe(WWF/TRAFFIC Germany, 2002).The species is endangered or criticallyendangered over most of its range; it isincluded in the Red Data Books ofBulgaria, Albania and Transcarpathia;wild harvest is banned in Montenegro;the species is protected by law inSerbia and the Ukraine and it isconsidered threatened in Turkey.Gentiana lutea is recorded in cultivationin 48 botanic gardens (PlantSearchdatabase). The gathering ofpropagation data from these gardensand the exchange of this in<strong>for</strong>mationwill help to ensure the ex situconservation of this species and willsupport restoration and reintroductionef<strong>for</strong>ts. BGCI aims to facilitate thiswork though its medicinal plantsprogramme.8<strong>Plants</strong> <strong>for</strong> <strong>life</strong>: Medicinal plant conservation and botanic gardens